Skip to main content

Advertisement

SpringerLink
Log in

Metalloproteinases and plasminogen activators in vessel remodeling

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Remodeling of blood vessels underlies the pathogenesis of major cardiovascular disorders, including atherosclerosis, restenosis, and hypertension. Because remodeling of arteries is highly dependent on degradation of the extra-cellular matrix, which enables cells to migrate and proliferate, there is intense interest in the regulation and the roles of matrix metalloproteinases (MMPs) and the plasminogen activator-plasmin (PA-P) systems in vessel remodeling. Factors that promote vessel remodeling have been shown to be important in upregulating the activities of both proteolytic systems and include chronic changes in hemodynamics, vessel injury, cytokines involved in inflammation, and elevations in reactive oxygen species. The two proteolytic systems utilize common transcription factors to activate their respective genes and are frequently coexpressed in remodeling and atherosclerotic arteries. In this review, we discuss the effects of activating the MMP and PA-P systems on processes involved in vascular remodeling, factors regulating their expression and activation, their roles in restenosis, and the development and progression of atherosclerosis, as well as the ability of currently available inhibitors to prevent unfavorable remodeling and atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Silence J, Lupu F, Collen D, et al.: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001, 21:1389–1392.

    Google Scholar 

  2. Vu TH, Werb Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123–2133.

    Article  PubMed  CAS  Google Scholar 

  3. Brew K, Dinakarpandian D, Nagase HU: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267–283.

    PubMed  CAS  Google Scholar 

  4. Oh J, Takahashi R, Kondo S, et al.: The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789–800.

    Article  PubMed  CAS  Google Scholar 

  5. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circ Res 2003, 92:827–839.

    Article  PubMed  CAS  Google Scholar 

  6. Xu J, Rodriguez D, Petitcleric E, et al.: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001, 154:1069–1079.

    Article  PubMed  CAS  Google Scholar 

  7. Levi E, Fridman R, Miao HQ, et al.: Matrix metalloproteinase-2 releases active soluble ectodomain of fibroblast growth factor receptor-1. Proc Natl Acad Sci U S A 1996, 93:7069–7074.

    Article  PubMed  CAS  Google Scholar 

  8. Linjnen HR, Ugwu F, Bini A, Collen D: Generation of an angiostatin-like fragment from plasminogen activator by stromolysin-1 (MMP-3). Biochemistry 1998, 37:7231–7236.

    Article  Google Scholar 

  9. Fernandez-Patron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85:906–911.

    PubMed  CAS  Google Scholar 

  10. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degradative activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493–2503.

    PubMed  CAS  Google Scholar 

  11. Brown DL, Hibbs MS, Kearney M, et al.: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125–2131.

    PubMed  CAS  Google Scholar 

  12. Zaltsman AB, Newby AC: Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis 1997, 130:61–70.

    Article  PubMed  CAS  Google Scholar 

  13. Carmeliet P, Moons L, Lijnen R, et al.: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997, 17:439–444.

    Article  PubMed  CAS  Google Scholar 

  14. Collen D: Role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology 2001, 1–9.

  15. Kienast J, Padro T, Steins M, et al.: Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost 1998, 79:579–586.

    PubMed  CAS  Google Scholar 

  16. Falkenberg M, Tom C, DeYoung MB, et al.: Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci U S A 2002, 99:10665–10670. Results of this study indicate that antagonists of uPA might be useful in limiting intimal growth and preventing constrictive remodeling associated with atherosclerosis. It is suggested that overexpression of uPA in endothelial cells, although potentially useful in preventing intravascular thrombosis, could worsen the underlying vascular disease.

    Article  PubMed  CAS  Google Scholar 

  17. Southgate KM, Mehta D, Izzat MB, et al.: Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 1999, 19:1640–1649.

    PubMed  CAS  Google Scholar 

  18. Rajavashisth TB, Xu XP, Jovinge S, et al.: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999, 99:3103–3109.

    PubMed  CAS  Google Scholar 

  19. Westermarck J, Kahari V: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781–792.

    PubMed  CAS  Google Scholar 

  20. Bond M, Chase AJ, Baker AH, et al.: Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3, and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001, 50:556–565.

    Article  PubMed  CAS  Google Scholar 

  21. Han YP, Nien YD, Garner WL: Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by downregulating tissue inhibitor of metalloproteinase-1 and mediated by tissueassociated chymotrypsin-like proteinase. J Biol Chem 2002, 277:27319–27327.

    Article  PubMed  CAS  Google Scholar 

  22. Sato N, Maehara N, Su GH, Goggins M: Effects of aza-2’-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 2003, 95:327–330.

    Article  PubMed  CAS  Google Scholar 

  23. Lengyel E, Klostergaard J, Boyd D: Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta 1995, 1268:65–72.

    Article  PubMed  Google Scholar 

  24. Kitange G, Shibata S, Tokunaga Y, et al.: Ets-1 transcription factormediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Lab Invest 1999, 79:407–416.

    PubMed  CAS  Google Scholar 

  25. Oka H, Kugiyama K, Doi H, et al.: Lysophosphatidylcholine induces urokinase type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arterioscler Thromb Vasc Biol 2000, 20:244–250.

    PubMed  CAS  Google Scholar 

  26. Khan KM, Falcone GJ: Role of laminin in matrix induction of macrophage-type plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem 1997, 272:8270–8275.

    Article  PubMed  CAS  Google Scholar 

  27. Chesler N, Ku D, Galis ZS: Transmural pressure induces matrix degrading activity in porcine arteries. Am J Physiol 1999, 277:H2002-H2009.

    PubMed  CAS  Google Scholar 

  28. Redmond EM, Cahill PA, Hirsch M, et al.: Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. Thromb Haemost 1999, 81:293–300.

    PubMed  CAS  Google Scholar 

  29. Galis ZS, Johnson C, Godin D, et al.: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002, 91:852–859. This study used animals deficient in MMP-9 to examine its role in vascular remodeling in a carotid flow cessation model. The study demonstrates that MMP-9 is essential for intima growth, the migration of smooth muscle cells, and the vascular remodeling that compensates for the development of intimal lesions.

    Article  PubMed  CAS  Google Scholar 

  30. Rajagopalan S, Meng XP, Ramasamy S, et al.: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996, 98:157–163.

    Article  Google Scholar 

  31. Tronc F, Mallat Z, Lehoux S, et al.: Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol 2000, 20:E120-E126.

    PubMed  CAS  Google Scholar 

  32. Frears ER, Zhang Z, Blake DR, et al.: Inactivation of tissue inhibitor of metalloproetinase-1 by peroxynitrite. FEBS Lett 1996, 381:21–24.

    Article  PubMed  CAS  Google Scholar 

  33. Chase AJ, Bond M, Crook MF, et al.: Role of nuclear factorkappaB activation in metalloproteinase-1, -3 and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002, 22:765–771. This study utilized adenovirus-mediated gene transfer of the NF-κB subunit, IκBα, to study the significance of NF-κB signaling for MMP production in macrophage-derived foam cells. The study demonstrates that secretion of MMP-1 and MMP-3, but not MMP-9 by macrophagederived foam cells, is dependent on activation of NF-κB, and suggests that this might be an attractive target to prevent unstable atheromas.

    Article  PubMed  CAS  Google Scholar 

  34. Shah PK, Falk E, Badimon JJ, et al.: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92:1565–1569.

    PubMed  CAS  Google Scholar 

  35. Shoufuda K, Nagashima Y, Kawahara K, et al.: Elevated expression of membrane-type 1 and 3 matrix metalloproteinases in rat vascular smooth muscle cells activated by arterial injury. Lab Invest 1998, 78:915–923.

    Google Scholar 

  36. Wang H, Keiser JA: Expression of membrane-type matrix metalloproteinase in rabbit neointimal tissue and its correlation with matrix-metalloproetinase-2 activation. J Vasc Res 1998, 35:45–54.

    Article  PubMed  CAS  Google Scholar 

  37. Plekhanova O, Parfyonova Y, Bibilashvily R, et al.: Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 2001, 159:297–306. In this study, several recombinant forms of uPA were used to demonstrate that uPA enhances intima growth in injured arteries by promoting cell migration and that this effect is highly dependent on its proteolytic activity.

    Article  PubMed  CAS  Google Scholar 

  38. Webb KE, Henney AM, Anglin S, et al.: Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol 1997, 17:1837–1844.

    PubMed  CAS  Google Scholar 

  39. Zempo N, Koyama N, Kenagy RD, et al.: Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996, 16:28–33.

    PubMed  CAS  Google Scholar 

  40. Mason DP, Kenagy RD, Hasenstab D, et al.: Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res 1999, 85:1179–1185.

    PubMed  CAS  Google Scholar 

  41. Lijnen HR, Van Hoef B, Lupu F, et al.: Function of the plasminogen/ plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998, 18:1035–1045.

    PubMed  CAS  Google Scholar 

  42. Amorino GP, Hoover RL: Interactions of monocytic cells with human endothelial cells stimulate monocyte metalloproteinase production. Am J Pathol 1998, 152:199–207.

    PubMed  CAS  Google Scholar 

  43. Pasterkamp C, Schoneveld AH, Hijnen DJ, et al.: Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinase 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000, 150:245–253.

    Article  PubMed  CAS  Google Scholar 

  44. Prescott MF, Sawyer WK, Von Linden-Reed J, et al.: Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12 and MMP-13 and on restenosis in rats after balloon injury. Ann NY Acad Sci 1999, 878:179–190.

    Article  PubMed  CAS  Google Scholar 

  45. Ghilardi G, Biondi ML, DeMonti M, et al.: Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002, 33:2408–2412. This study suggests that patients homozygous for the 6A allele in the MMP-3 promoter (reduced transcriptional activity) are at greater risk for developing stenosis in the internal carotid arteries, and this is further increased if they are also homozygous for the 2G allele of MMP-1 (increased transcriptional activity).

    Article  PubMed  CAS  Google Scholar 

  46. Humphries SE, Luong LA, Talmud PJ, et al.: The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lipid Coronary Angiography Trial. Atherosclerosis 1998, 139:49–56.

    Article  PubMed  CAS  Google Scholar 

  47. Zhang B, Ye S, Herrmann SM, et al.: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788–1794.

    PubMed  CAS  Google Scholar 

  48. Hasenstab D, Lea H, Clowes AW: Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc Biol 2000, 20:853–859.

    PubMed  CAS  Google Scholar 

  49. Forough R, Lea H, Starcher B, et al.: Metalloproteinase blockade by local overexpression of TIMP-1 increases elastin accumulation in rat carotid artery intima. Arterioscler Thromb Vasc Biol 1998, 18:803–807.

    PubMed  CAS  Google Scholar 

  50. Hu Y, Baker AH, Zou Y, et al.: Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 2001, 21:1275–1280. This study demonstrates that overexpression of TIMP-2 in vein grafts in mice markedly reduces the elevated matrix metalloproteinase activity, attenuates the reduction in lumen diameter, and significantly reduces remodeling of the vein to an artery-like vessel with a large intima.

    PubMed  CAS  Google Scholar 

  51. De Smet BJ, de Kleijn D, Hanemaaijer R, et al.: Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 2000, 101:2962–2967.

    PubMed  Google Scholar 

  52. Rouis M, Adamy C, Duverger N, et al.: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999, 100:533–540.

    PubMed  CAS  Google Scholar 

  53. Lemaitre V, O’Byrne TK, Borczuk AC, et al.: ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001, 107:1227–1234. This study utilized transgenic ApoE-/-mice whose macrophages overexpress MMP-1 to study its role in the development of atherosclerotic lesions. Rather than augmenting atherosclerotic lesions, the mice overexpressing MMP-1 exhibited less extensive and more immature lesions with a diminished content of fibrillar collagen and no evidence of plaque rupture, suggesting an antiatherogenic role for MMP-1.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cell Biology Laboratory, Baker Heart Research Institute, St Kilda Road Central, PO Box 6492, 8008, Melbourne Victoria, Australia

    Alex Bobik PhD & Vselovod Tkachuk DSc

Authors
  1. Alex Bobik PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vselovod Tkachuk DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bobik, A., Tkachuk, V. Metalloproteinases and plasminogen activators in vessel remodeling. Current Science Inc 5, 466–472 (2003). https://doi.org/10.1007/s11906-003-0054-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0054-5

Keywords

Search

Navigation